Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly covered in the literature. However, the accepted classification of ITP-childhood ITP and adult ITP -results in considerable differences in treatment protocols and practice guidelines. The analysis of the Pediatric and Adult Registry on Chronic ITP (PARC-ITP) of patients at first presentation demonstrated fewer differences in clinical and laboratory findings at initial diagnosis between children and adults than expected. The present report of 2-year follow-up data supports the hypothesis that there are common aspects of childhood and adult ITP. Data of 3360 children and 420 adults were collected during the time of 2004 until 2015 at initial diagnosis. Follow-up information was available for 51% and 33% of children and 66% and 49% of adults at 12-and 24-months, respectively. Similarities were found in unexpected areas of ITP, such as the rate of late remission at 12 and 24 months, reported bleeding sites, platelet count in bleeders, and the frequency of treated patients with persistent or chronic ITP. Differences were confirmed for the overall rate of remission and treatment modalities. Unexpected differences were found in the percentage of nonbleeders, with more adults in the nonbleeder group. More studies are needed to investigate different age groups with the aim to optimize their management.
destruction, T-and B-cell abnormalities with disturbed cytokine profiles, and impaired megakaryopoiesis. [1] [2] [3] [4] [5] Clinically, ITP of children differs from that of adults in spontaneous remission rate, bleeding pattern, and treatment need. [6] [7] [8] [9] [10] While approximately 80% of children are disease-free within 1 year, most adults (70%-80%) show a chronic course. 11 Adults have a higher bleeding risk; thus, pharmacological treatment and splenectomy are more often required in adults than in children, 9 ,10 whereas a watch and wait strategy is a standard approach for children with no or mild bleeding. 9, 10 However, some of these clinical presumptions are limited by inconsistent study designs, study populations, collected information (e.g., bleeding assessment tools), definitions, study objectives, and end-points. Initial data of the Pediatric and Adult Registry on Chronic ITP (PARC-ITP) were previously published and demonstrated considerably smaller differences in clinical and laboratory findings at disease onset between children and adults than expected. 12 Moreover, recent studies showed that the severity of thrombocytopenia at diagnosis was a predictor of recovery from ITP in both children and adults. 13, 14 The classification of pediatric and adult ITP may not adequately reflect clinical requirements. Sub-classifying patients based on phenotypic characteristics, including insidious or abrupt onset and grade of bleeding, describe ITP more accurately and consequently affect management decisions and probably better predict persistent or chronic ITP.
Understanding differences and similarities between children and adults with ITP will improve individual diagnosis and management. We aimed to assess and interpret comparative follow-up (FU) PARC-ITP Registry data in children and adults with ITP.
| M E TH ODS
The PARC-ITP is an international multi-center registry designed to collect data prospectively in children and adults with newly diagnosed ITP. ICIS is meanwhile well-established and active at various scientific congresses, and holds expert meetings every 3 years. [15] [16] [17] [18] [19] The protocol, registration of data, and all registry documents are available via secure internet access (www.parc-itp.net). Data acquisition by investigators was performed by direct internet access into a database that is administered in the ICIS office in Basel, Switzerland (www.itpbasel.ch). Data are continuously registered at the time of diagnosis, at 6 and 12 months, and then yearly and include demographics, diagnostics, clinical data, and safety data of treatments. The questionnaires' structure is limited by a certain number of questions to maintain feasibility data transfer and collaboration of investigators.
Data quality controlling and cleaning is performed at the office in Basel. ITP was defined according to the International Working Group (IWG) definitions. 20 Patients with missing FU data at certain time points (6, 12 , and 24 months) were included in the analysis (Supporting Information Figure S1A ). Secondary ITP was excluded from registration; patients in whom the diagnosis was revised from primary to secondary ITP or thrombocytopenia of other cause during FU were prospectively identified, and not excluded from the analysis. Ethical committee approval and informed consent were received from all patients. 12, 21 Data are reported using descriptive statistics. Frequencies and percentages are reported for counts and categorical variables. Continuous variables are reported as mean 6 standard deviation (SD). Median and interquartile range (IQR) are reported for age and platelet count in Table 1 .
Categorical variables were analyzed using Chi-square tests. Continuous variables between groups were compared using the nonparametric Wilcoxon's test. Cumulative incidences between groups were compared using the nonparametric log-rank test. A P-value of <.05
was considered statistically significant. Analyses were performed using R Development Core Team, version 3.4.0. 22 
| Definitions
If not mentioned otherwise, the definitions of the IWG were used. 20 Patients were divided into two groups according to age at initial diagnosis. Children were defined as 3 months to 16 years of age, and adults as >16 years. For certain analyses, the adult group was divided into three subgroups including young adults (16-40 years), midlife adults (40-60 years), and seniors (> 60 years). Age refers to the age at first presentation of ITP, equating to the initial visit.
FU data at 6 months summarize the clinical course (e.g., bleeding
and management) of the disease in the first 6 months (excluding information at initial diagnosis); FU data at 12 months summarize the clinical course during >6-12 months, and FU data at 24 months include the time during >12-24 months. Platelet counts were registered as a single value (mean 6 SD) at approximately 6 (175 6 47 days), 12 (365 6 66 days), and 24 months (722 6 59 days).
Remission of ITP: "Remission" in an autoimmune disease refers to the reoccurrence of tolerance and is difficult or even impossible to measure. We used the term "remission" to define ITP activity as assessed by the platelet count irrespective of prior or ongoing therapy. According to our definition, a platelet count of >100 3 10 9 /L at 6, 12, and 24 months of follow-up visits is considered a "remission."
Persistent ITP was defined as a platelet count <100 3 10 9 /L at 6 months, and chronic disease as a platelet count <100 Table S1 . FU information was available for the 6-, 12-, and 24-month evaluations in 68%, 51%, and 33% of children and 79%, 66%, and 49% of adults, respectively (Supporting Information Figure S1B ). co-medication rate (3.6%) similar to that of children compared with midlife adults (10.9%) and seniors (36.2%). Anti-inflammatory drug use only (e.g., NSAIDs) was reported in 60% of adults and 97% of children in whom relevant co-medication was reported.
| Initial patient characteristics
Co-morbidities were reported in 360 children, 32 young adults, 42 midlife adults, and 55 seniors (10.7%, 12.8%, 41.6%, and 79.7%, respectively).
| Lost to FU
Lost to FU was significantly higher in patients achieving remission of ITP. At 6 and 12 months, remission rates in children subsequently lost to FU were 87% and 82%, respectively (chi-square test comparing remission state of patients with and without FU, P < .001 at both time points). In adults, remission rates were 64% (P 5 .008) and 56% (P 5 .15), respectively. Among all patients with persistent ITP at 6 months, FU information at 12 and/or 24 months was provided for 90% of children and adults. Comparison of the initial characteristics between patients with FU data and patients lost to FU at 6 months found that children lost to FU had a lower age, higher initial mean platelet count, lesser initial bleeding, and lesser initial drug treatment (Table 1 ).
| Natural history: Remission and ongoing disease
The characteristics of patients in remission and with ongoing disease at 12 months are shown in Table 2 and mean platelet counts at all FU are depicted in Figure 1A . Patients in remission at 6, 12, and 24 months consisted of 70%, 71%, and 71% of children and 45%, 49%, and 56% of adults, respectively. Among the patients with persistent ITP, 212/592 (36%) children and 42/155 (27%) adults achieved remission at 12 months. Late remission at 24 months was reported in 83/298 (28%) and 26/87 (30%) adults. The cumulative incidence of remission was significantly different between children and adults (P < .001) and is demonstrated in Figure 2 . For this analysis, patients achieving remission at 6 and/or 12 months and consequently lost to FU were presumed to be still in remission at the 24-month FU.
In children, mean age of patients with late remission at 12 and 24 months was higher (6.9 6 4.7 years) than that of children with reported early remission at 6 months (4.8 6 4 years) (P < .001). Children with persistent ITP had a mean age of 7.2 6 4.6 years. Adults with early remission at the 6-month FU had a mean age of 37.9 618.5 years and those with a late remission at 12 and 24 months had a mean age of 40.4 6 20.4 years, which was not significant (P 5 .45).
Mean platelet count in patients with ongoing ITP was very similar in children and adults at the 12-month FU: 46 6 29 3 10 9 /L and 51 6 26 3 10 9 /L, respectively. Children in remission showed a higher platelet count at all FU examinations compared with adults ( Figure 1A ).
| Bleeding manifestations
Approximately 37% and 36% of children diagnosed with chronic ITP reported no bleeding at 12 and 24 months, respectively. A higher percent of adults with chronic ITP had no bleeding manifestations (69% and 64%
at 12 and 24 months, respectively) (P < .001 at both time points). Children and adults achieving remission showed very similar percentages of nonbleeders at all reported FU examinations (e.g., Table 2 ).
The bleeding sites showed similarities in children and adults at all FU examinations (Supporting Information Table S2 ). Table S3 .
Co-morbidities did not appear to affect bleeding in children or
adults; approximately 69% and 66% of children and 44% and 43% of adults with and without co-morbidities with persistent ITP at 6 months reported bleeding, respectively. This was also observed in adults on relevant co-medication; only 22% of adults diagnosed with chronic ITP and taking relevant co-medication reported a bleeding event compared with 32% of those without co-medication. The group of children on relevant co-medication was too small for a detailed analysis.
| Management
Platelet-enhancing drug treatment was reported at the 6-month FU (initial treatment not included), 12-and 24-month FU in 30%, 19%, and 19% of children and in 59%, 40%, and 33% of adults, respectively. However, for patients with ongoing ITP, treatment did not differ between children and adults (58%, 46%, and 47%; and 58%, 52%, and 40% at the three FU examinations, respectively). Women with ongoing disease were more often treated than men ( Table 2 ). The platelet counts of treated and untreated patients with chronic ITP are shown in Figure 1B .
| First-line treatment (corticosteroids and IVIG)
Corticosteroids were prescribed in 19% of children and 49% of adults during the first 6 months of the disease (initial treatment excluded). Cumulative incidence of remission. The cumulative incidence of remission was significantly different between children and adults (log-rank test, P < .001). For this analysis it was assumed that patients achieving remission at 6 or12 months and consecutively lost to FU were still in remission at 24 months FU. It is of note that patients lost to FU at 12 and 24 months had a higher remission rate in the previous FU than patients with FU data [Color figure can be viewed at wileyonlinelibrary.com] SCHIFFERLI ET AL.
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Corticosteroid use decreased in both children and adults over time, with 12% and 11% of children and 33% and 21% of adults receiving corticosteroids at 12 and 24 months, respectively. However, the proportion of patients receiving corticosteroids in the group of patients requiring treatment remained high at all three FU examinations (adults, 83%, 81%, and 65%; and children, 65%, 63%, and 56%, respectively).
Immunoglobulin (IVIG and anti-D) use was higher in children than in adults at all three FU examinations (e.g., Table 2 ).
| Second (third)-line treatment
Second (third)-line drug treatment was reported in 38%, 47%, and 44%
of treated children and 67%, 74%, and 72% of adults at 6-, 12-, and 24-month FU, respectively. The modality of treatment was not analyzed for this report. Splenectomy was performed in 4 children and 23
adults within the first 6 months (0.2% and 7.1% of children and adults). Differences between pediatric and adult ITP have been traditionally emphasized 6 and appear to be opinion-based rather than evidencebased. [7] [8] [9] [10] Incongruity of definitions and lack of comparative data might have further contributed to the separation of childhood and adulthood ITP. 25 In most textbooks, 26,27 pediatric ITP is described as an acute and profound but self-limiting thrombocytopenia following a viral infection, with a low life-threatening bleeding risk. In contrast, adult ITP is described as a chronic disease with an insidious onset and a moderate thrombocytopenia, sometimes detected as an incidental thrombocytopenia, a high bleeding risk for patients with a platelet count <30 3 10 9 /L (40), and increased morbidity and mortality, particularly in patients aged >60 years. 11, 25, 28, 29 Current concepts of pediatric and adult ITP resulted in treatment protocols and practice guidelines with clinically relevant differences between these groups. [7] [8] [9] [10] PARC-ITP first data analysis of children and adults with newly diagnosed ITP revealed surprising similarities in presenting platelet count, likelihood of overall bleeding when platelets were <20 3 10 9 /L, and percentage of patients who remained untreated in both populations. 12 Patients differed with regard to co-morbidities and initial treatment modality. Pediatric and adult ITP seem to share more common clinical and laboratory aspects than previously presumed. This report is an analysis of FU data and supports the hypothesis of common aspects among children and adults. Similarities were found in many unexpected areas of ITP regarding natural history, including late remission rate at 12 and 24 months, reported bleeding sites, platelet count in bleeders, and need to treat patients with persistent or chronic ITP. Differences were confirmed for the overall remission rate and treatment modalities.
Unexpected differences were found regarding the percentage of nonbleeders.Age group were arbitrary chosen. The age of thepediatric cohort corresponds to data previously reported in the literature, 30 the adult cohort was slightly younger than that reported, e.g., by Abrahamson and coworkers, 31,32 the difference here could be explained based on our definition of adults aged >16 years.
| Remission
Remission rate in adults (45% at 6-month FU) was higher than expected. 6, 7 In adults, we could not differentiate patients in remission still receiving ITP treatment from those with sustained remission after discontinuing treatment. In children, remission rate was comparable to earlier reports, 33 so as differences in age between patients with early remission (until 6 months) and those with persistent or chronic disease (4.9 6 4 years, 7.2 6 4.6 years, and 7.4 1 4.5 years, respectively). 33 Children with late remission (at 12 or 24 months) were older (6.9 6 4.7 years) than patients with early remission in our cohort.
Late remission at 12-and 24-month FU examinations was very similar in children (36% and 28% of patients with ongoing ITP at the previous FU) and adults (28% and 30%). Late remission data in adults are scarce, 34 and this is neglected in some publications involving therapeutic recommendations, particularly the time point of splenectomy. 8, 10 Sailer et al. 34 showed that between 6 months and 3 years after diagnosis, adults with severe ITP (<20 3 10 9 /L platelets) had a 0.5% chance per month of obtaining complete remission during treatment with or without low-dose steroids and reported a 61% cumulative probability of complete remission in not splenectomized patients. In children, ICIS reported a late remission rate of 16%-25% between 6 and 12 months 33, 35 and 24% between 12 and 24 months 24 ; however, the definition of remission was a platelet count >150 3 10 9 /L, which may explain the small difference with our study.
| Bleeding
Definition, assessment, and grading of bleeding in patients with ITP has been developed with consensus conferences 20 and use of bleeding scores. 36, 37 Unfortunately, there is no consensus on which bleeding assessment tool should be used in a routine clinical setting and at which time point or in which clinical situation bleeding should be assessed. Bleeding assessment is further hindered by the lack of clear inclusion criteria of study populations. 28, [38] [39] [40] [41] We focused on the analysis of nonbleeders because the definition is clearer. However, diagnosing a "nonbleeder" requires a complete clinical assessment. 45, 46 ; however, recent data suggest that <25%
of patients with ITP undergo splenectomy, mostly with a delay from second-to third-line treatment. 47 The reason for this decline are probably various, medical professionals recommend increasingly to delay splenectomy but also patients do not accept uncritically the procedure.
The optimal role of splenectomy in chronic ITP treatment in the current era of TPO-RAs still has to be determined. Of concern was early splenectomy at the 6-month FU in 4 children and 23 adults. This is not in accordance with current guidelines. Following this strategy, we used statistical evaluation for selected and clearly defined issues only.
In conclusion, understanding differences and similarities among different age groups with ITP during FU may be valuable in characterizing study populations and in better defining inclusion criteria for trials and further individualizing diagnosis and management. Future studies will investigate criteria to better define age groups.
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